Document is current
Any future updates will be listed below
-
Authors
Rigo, Antonella
Vaisitti, Tiziana
Laudanna, Carlo
Terrabuio, Eleonora
Micillo, Matilde
Frusteri, Cristina
D’Ulivo, Beatrice
Merigo, Flavia
Sbarbati, Andrea
Mellert, Kevin
Möeller, Peter
Montresor, Alessio
Di Napoli, Arianna https://orcid.org/0000-0002-3159-5380
Cirombella, Roberto
Butturini, Elena
Massaia, Massimo
Constantin, Gabriela
Vinante, Fabrizio
Deaglio, Silvia https://orcid.org/0000-0003-0632-5036
Ferrarini, Isacco https://orcid.org/0000-0001-9867-8335
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (MFAG #23107, IG #23095)
Research Projects of Relevant National Interest
National Recovery and Resilience Plan (PNRR) National Centers Program PNRR “Partenariati estesi” Program, grant MNESYS
- License Information
-
More Information
Article History
Received: 20 November 2023
Revised: 20 April 2024
Accepted: 24 April 2024
First Online: 9 May 2024
Competing interests
: IF received research funding from AbbVie. The other authors declare no competing financial interest.
: The study was approved by the local ethics committee (protocol #1747CESC, AOUI Verona) and written informed consent was obtained from all enrolled patients. Mouse models of Richter syndrome (RS-PDXs) were generated and treated according to the European guidelines for animal use in scientific research, and with the approval of the Italian Ministry of Health (authorization #664/2020; protocol #CC652.136).
